Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740884 | 0.90 | MTNR1A (0.44) | MTNR1AMTNR1BMAPTNAMPTCKS1B | |
| SCHEMBL25808542 | 0.90 | MTNR1A (0.44) | MTNR1AMTNR1BMAPTNAMPTCKS1B | |
| SCHEMBL16494745 | 0.84 | CYP2D6 (0.50) | MAPTNCF1NAMPTGSK3BTDP1 | |
| SCHEMBL48633 | 0.83 | — | — | |
| SCHEMBL13165688 | 0.83 | TDP1 (0.58) | MTNR1AMTNR1BCKS1BSKP1SKP2 | |
| SCHEMBL23173065 | 0.82 | MAPT (0.43) | MAPTNCF1NAMPTGSK3BTDP1 | |
| SCHEMBL7699802 | 0.82 | TDP1 (0.45) | MTNR1AMTNR1BCKS1BSKP1SKP2 | |
| SCHEMBL13621194 | 0.82 | TDP1 (0.67) | MAPTNCF1NAMPTGSK3BTDP1 | |
| SCHEMBL14252423 | 0.82 | CKS1B (0.45) | MTNR1AMTNR1BCKS1BSKP1SKP2 | |
| SCHEMBL21974977 | 0.82 | CKS1B (0.42) | MTNR1AMTNR1BCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023138412-A1 | FUSED PYRIMIDIN-2-AMINE COMPOUNDS AS CDK20 INHIBITORS | INSILICO MEDICINE IP LIMITED (CN) | 2023-07-27 | — | — | WO | disclosed |
| CN-116472063-A | Targeted conjugates comprising modified siRNAs | 阿布特斯生物制药公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023093787-A1 | BENZODIAZEPINE COMPOUND AND APPLICATION THEREOF AS RHO KINASE INHIBITOR | 成都奥睿药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | BP ASSET V, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| EP-3915992-A1 | PDE9 INHIBITOR AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021146629-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021097009-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070142392-A1 | Uses of rifamycins | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142392-A1 | Uses of rifamycins | TNF, TLR6, IL6 | MTNR1A 4360/4885MTNR1B 4178/4885MAPT 4424/4885 |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | FURIN, LGMN, PLAU | MTNR1A 2172/4885MTNR1B 3209/4885MAPT 1193/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MTNR1A 108/4885MTNR1B 58/4885MAPT 4057/4885 |
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | FURIN, ACE, ACE2 | MTNR1A 4411/4885MTNR1B 4437/4885MAPT 2816/4885 |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | MTNR1A 3828/4885MTNR1B 3400/4885MAPT 3706/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MTNR1A 1839/4885MTNR1B 1687/4885MAPT 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.